3zm5: Difference between revisions
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== | ==CRYSTAL STRUCTURE OF MURF LIGASE IN COMPLEX WITH CYANOTHIOPHENE INHIBITOR== | ||
[[http://www.uniprot.org/uniprot/Q8DNV6_STRR6 Q8DNV6_STRR6 | <StructureSection load='3zm5' size='340' side='right'caption='[[3zm5]], [[Resolution|resolution]] 2.94Å' scene=''> | ||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3zm5]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae_R6 Streptococcus pneumoniae R6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ZM5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3ZM5 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.94Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=IGM:2,4-BIS(CHLORANYL)-N-[3-CYANO-6-[(4-HYDROXYPHENYL)METHYL]-5,7-DIHYDRO-4H-THIENO[2,3-C]PYRIDIN-2-YL]-5-MORPHOLIN-4-YLSULFONYL-BENZAMIDE'>IGM</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3zm5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3zm5 OCA], [https://pdbe.org/3zm5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3zm5 RCSB], [https://www.ebi.ac.uk/pdbsum/3zm5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3zm5 ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/Q8DNV6_STRR6 Q8DNV6_STRR6] Involved in cell wall formation. Catalyzes the final step in the synthesis of UDP-N-acetylmuramoyl-pentapeptide, the precursor of murein (By similarity).[RuleBase:RU004136] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Peptidoglycan is an essential component of the bacterial cell wall, and enzymes involved in its biosynthesis represent validated targets for antibacterial drug discovery. MurF catalyzes the final intracellular peptidoglycan biosynthesis step: the addition of d-Ala-d-Ala to the nucleotide precursor UDP-MurNAc-l-Ala-gamma-d-Glu-meso-DAP (or l-Lys). As MurF has no human counterpart, it represents an attractive target for the development of new antibacterial drugs. Using recently published cyanothiophene inhibitors of MurF from Streptococcus pneumoniae as a starting point, we designed and synthesized a series of structurally related derivatives and investigated their inhibition of MurF enzymes from different bacterial species. Systematic structural modifications of the parent compounds resulted in a series of nanomolar inhibitors of MurF from S. pneumoniae and micromolar inhibitors of MurF from Escherichia coli and Staphylococcus aureus. Some of the inhibitors also show antibacterial activity against S. pneumoniae R6. These findings, together with two new co-crystal structures, represent an excellent starting point for further optimization toward effective novel antibacterials. | |||
Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF.,Hrast M, Turk S, Sosic I, Knez D, Randall CP, Barreteau H, Contreras-Martel C, Dessen A, O'Neill AJ, Mengin-Lecreulx D, Blanot D, Gobec S Eur J Med Chem. 2013 May 21;66C:32-45. doi: 10.1016/j.ejmech.2013.05.013. PMID:23786712<ref>PMID:23786712</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
< | </div> | ||
[[Category: | <div class="pdbe-citations 3zm5" style="background-color:#fffaf0;"></div> | ||
[[Category: | |||
[[Category: Barreteau | ==See Also== | ||
[[Category: Blanot | *[[Mur ligase|Mur ligase]] | ||
[[Category: Contreras-Martel | == References == | ||
[[Category: Dessen | <references/> | ||
[[Category: Gobec | __TOC__ | ||
[[Category: Hrast | </StructureSection> | ||
[[Category: Knez | [[Category: Large Structures]] | ||
[[Category: Mengin-Lecreulx | [[Category: Streptococcus pneumoniae R6]] | ||
[[Category: ONeill | [[Category: Barreteau H]] | ||
[[Category: Randall | [[Category: Blanot D]] | ||
[[Category: Sosic | [[Category: Contreras-Martel C]] | ||
[[Category: Turk | [[Category: Dessen A]] | ||
[[Category: Gobec S]] | |||
[[Category: Hrast M]] | |||
[[Category: Knez D]] | |||
[[Category: Mengin-Lecreulx D]] | |||
[[Category: ONeill AJ]] | |||
[[Category: Randall CP]] | |||
[[Category: Sosic I]] | |||
[[Category: Turk S]] | |||
Latest revision as of 14:05, 20 December 2023
CRYSTAL STRUCTURE OF MURF LIGASE IN COMPLEX WITH CYANOTHIOPHENE INHIBITORCRYSTAL STRUCTURE OF MURF LIGASE IN COMPLEX WITH CYANOTHIOPHENE INHIBITOR
Structural highlights
FunctionQ8DNV6_STRR6 Involved in cell wall formation. Catalyzes the final step in the synthesis of UDP-N-acetylmuramoyl-pentapeptide, the precursor of murein (By similarity).[RuleBase:RU004136] Publication Abstract from PubMedPeptidoglycan is an essential component of the bacterial cell wall, and enzymes involved in its biosynthesis represent validated targets for antibacterial drug discovery. MurF catalyzes the final intracellular peptidoglycan biosynthesis step: the addition of d-Ala-d-Ala to the nucleotide precursor UDP-MurNAc-l-Ala-gamma-d-Glu-meso-DAP (or l-Lys). As MurF has no human counterpart, it represents an attractive target for the development of new antibacterial drugs. Using recently published cyanothiophene inhibitors of MurF from Streptococcus pneumoniae as a starting point, we designed and synthesized a series of structurally related derivatives and investigated their inhibition of MurF enzymes from different bacterial species. Systematic structural modifications of the parent compounds resulted in a series of nanomolar inhibitors of MurF from S. pneumoniae and micromolar inhibitors of MurF from Escherichia coli and Staphylococcus aureus. Some of the inhibitors also show antibacterial activity against S. pneumoniae R6. These findings, together with two new co-crystal structures, represent an excellent starting point for further optimization toward effective novel antibacterials. Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF.,Hrast M, Turk S, Sosic I, Knez D, Randall CP, Barreteau H, Contreras-Martel C, Dessen A, O'Neill AJ, Mengin-Lecreulx D, Blanot D, Gobec S Eur J Med Chem. 2013 May 21;66C:32-45. doi: 10.1016/j.ejmech.2013.05.013. PMID:23786712[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||